Multicenter retrospective cohort study of the sequential use of antibody drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2 low metastatic breast cancer (MBC): a subgroup analysis of next generation sequencing results.
Publication Date
12-10-2024
Presented At:
San Antonio Breast Cancer Symposium (SABCS)
Citation
Mahtani, Reshma; Zerey, Mehmet; Sandoval Leon, Ana Cristina; Carcas, Lauren; Panoff, Joseph; and Ahluwalia, Manmeet, "Multicenter retrospective cohort study of the sequential use of antibody drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2 low metastatic breast cancer (MBC): a subgroup analysis of next generation sequencing results." (2024). All Publications. 5487.
https://scholarlycommons.baptisthealth.net/se-all-publications/5487